@article {7914,
	title = {Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: Relationship with cell cycle regulators and prognostic implications},
	journal = {British Journal of Cancer},
	volume = {97},
	year = {2007},
	note = {Cited By :23Export Date: 21 February 2017},
	month = {2007},
	pages = {1124 - 1134},
	abstract = {Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in several tumour types. This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27Kip1, p21WAF1 and pRb) and patients{\textquoteright} outcome. Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas. Survival analysis was restricted to adenocarcinomas. The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in adenocarcinomas compared to LMP tumours (P\&lt;0.0001 for both associations). In adenocarcinomas, the levels of MCM-2 and MCM-5 increased significantly with advancing tumour stage (P=0.0052 and P=0.0180, respectively), whereas both MCM-2 and MCM-5 increased significantly with increasing tumour grade (P=0.0002 and P=0.0006, respectively) and the presence of bulky residual disease (P\&lt;0.0001 in both relationships). A strong positive correlation was established between MCM-2 or MCM-5 expression level and Ki-67 LI (P\&lt;0.0001) as well as p53 protein (P=0.0038 and P=0.0500, respectively). Moreover, MCM-2 LI was inversely correlated with p27Kip-1 LI (P=0.0068). Finally, both MCM-2 and MCM-5 were associated significantly with adverse patients{\textquoteright} outcome in both univariate (>=20 vs \&gt;20\%, P=0.0011 and >=25 vs \&lt;25\%, P=0.0100, respectively) and multivariate (P=0.0001 and 0.0090, respectively) analysis. An adequately powered independent group of 45 patients was used in order to validate our results in univariate survival analysis. In this group, MCM-2 and MCM-5 expression retained their prognostic significance (P\&lt;0.0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in patients with ovarian adenocarcinomas. {\textcopyright} 2007 Cancer Research UK.},
	keywords = {Ki-67, MCM-2, MCM-5, Ovarian adenocarcinomas, Ovarian low malignant potential tumours, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-35348830387\&doi=10.1038\%2fsj.bjc.6603992\&partnerID=40\&md5=a33b3b682ed4507dcde1915723b08259},
	author = {Gakiopoulou, H and P Korkolopoulou and G Levidou and Thymara, I. and Saetta, A. and Piperi, C. and Givalos, N. and Vassilopoulos, I. and Ventouri, K. and Tsenga, A. and Bamias, A. and Dimopoulos, M.-A. and Agapitos, E. and Patsouris, E.}
}
